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[Abstract] Leishmaniasis remains a major public health problem worldwide with a prevalence of 12 
million, an incidence of 1 million persons, and 350 million people being at risk. Murine models have been 
largely used for studying the host-pathogen relationship and developing effective chemotherapies 
against Leishmania parasites. Thus, preclinical imaging is crucial for monitoring the disease outcome. 
The aim of this protocol is to quantify parasite burden using bioluminescence in vivo imaging. Here, we 
describe a high-throughput imaging workflow, together with data acquisition and analysis ideal to assess 
in vivo parasite load in mouse models. 
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[Background] Leishmania parasites are the causative agents of the neglected tropical disease known 
as leishmaniasis. The disease outcome varies depending on different factors including the infecting 
species, the immune response of the host, the presence of an endosymbiotic virus within Leishmania 
parasites (Ives et al., 2011), or the co-infection with viruses such human immunodeficiency virus (HIV) 
or lymphocytic choriomeningitis mammarenavirus (LCMV) which can be detrimental for disease 
exacerbation (van Griensven et al., 2014; Rossi et al., 2017). Therefore, the study of parasite 
persistence using murine models has emerged in the past years (Eren et al., 2016). The quantification 
of parasite burden in experimental models of Leishmania infection has been commonly quantified by 
either Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) or by limiting dilution assays upon 
euthanasia of animals (Hartley et al., 2016). In this protocol, we report a non-invasive technique for the 
quantification of parasite burden during the disease progression using luciferase expressing parasites 
(Ives et al., 2011; Hartley et al., 2018). Moreover, this approach can also be applied for the in vivo 
detection of other chemiluminescent agents such as luminol that is used as a readout of 
myeloperoxidase (MPO) activity in acute and chronic inflammatory diseases, or for any other organism 
expressing luciferase. 
 
Materials and Reagents 
 
1. Eco Nitrile PF 250 Gloves (ecoSHIELDTM) 
2. Tissue culture flask 25 version “Vent” (TPP®, catalog number: 90025) 
3. Microcentrifuge 1.5 ml tubes (Corning, Axygen®, catalog number: MCT-175-C) 
4. 50 ml syringe (B. Braun Medical, catalog number: 4617509F-02) 
5. Polypropylene conical 15 ml centrifuge tube (TPP Techno Plastic Products, catalog number: 
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91015) 
6. Polypropylene conical 50 ml centrifuge tube (TPP Techno Plastic Products, catalog number: 
91050) 
7. BD Micro-FineTM + U-100 Insulin syringes 0.5 ml 0.33 mm (29G) x 12.7 mm (BD Medical, catalog 
number: 324824) 
8. 2 ml serological pipettes (FALCON®, catalog number: 357507) 
9. 10 ml serological pipettes (SARSTEDT, catalog number: 86.1254. 001) 
10. 25 ml serological pipettes (SARSTEDT, catalog number: 86.1685.001) 
11. 0.22 μm syringe-filter (Carl Roth, catalog number: P668.1) 
12. Vacuum Filtration 500 “rapid”-Filtermax, PES membrane 0.22 μm pore size (TPP®, catalog 
number: 99500) 
13. 6-9-week-old specific-pathogen free C57BL/6 female mice 
14. Dulbecco's Phosphate-Buffered Saline (DPBS) (Thermo Fisher Scientific, GibcoTM, catalog 
number: 14040091), stored at 4 °C 
15. Schneider’s Drosophila Medium w: L-Glutamine and 0.40 g/L NaHCO3 (PANTM BIOTECH, 
catalog number: P04-91500), store at 4 °C 
16. Fetal Bovine Serum (FBS) (Thermo Fisher Scientific, GibcoTM, catalog number: 10270106), 
stored at -20 °C 
17. HEPES Buffer (1M) (BioConcept, catalog Number: 5-31F00-H), stored at 4 °C 
18. Penicillin-Streptomycin (P/S) solution (10.000 IU/ml P/ 10 mg/ml S) (Bioconcept, catalog 
number: 4-01F00-H), stored at 4 °C  
19. Hemin BioXtra, from Porcine (Sigma-Aldrich, catalog number: 51280), stored at 4 °C 
20. Folic acid (FlukaTM, catalog number: 47620), stored at 4 °C 
21. 6-Biopterin (Sigma-Aldrich, catalog number: B2517), stored at -20 °C 
22. Dimethyl sulfoxide (DMSO) Cell culture grade (AppliChem GmbH, catalog number: A3672) 
23. Sodium hydroxide ≥ 98% p.a., ISO, in pellets (Carl Roth, catalog number: 6771.1) 
24. Glutaraldehyde solution technical, ~ 50% in H2O (5.6 M) (FlukaTM, catalog number: 49629), 
stored at 4 °C 
25. 70% Ethanol F25® (in H2O) (Alcosuisse) 
26. VivoGloTM Luciferin, in vivo Grade (Promega, catalog number: P1041), stored at -20 °C 
27. Luciferase-expressing transfectants of Leishmania guyanensis parasites M4147 
(MHOM/BR/75/M4147) 
28. AttaneTM Isoflurane ad us. vet. (Provet AG, catalog number: covetrus 722 2222) 
29. Complete parasite culture medium (see Recipes), stored at 4 °C 
30. Heat-inactivated FBS (see Recipes) 
31. Biopterin (see Recipes) 
32. Hemin-folate (see Recipes) 
33. Parasite fixative solution (see Recipes), stored at 4 °C 
34. Luciferin solution (see Recipes), stored at -20 °C 
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Equipment 
 
1. FormaTM Steri-CycleTM CO2 Incubator at 26 °C (Thermo Fisher Scientific, catalog number: 371) 
2. Pipette controller (INTEGRA, catalog number: 155017) 
3. Pipettes (Gilson®)  
4. Counting chamber improved Neubauer (Assistent®, catalog number: 40442) 
5. Centrifuge 5810 R (Eppendorf) 
6. Benchtop pH Meter (METTLER TOLEDO) 
7. Water Bath (Julabo) 
8. Laminar flow hood parasite culture (SafeFAST Premium) 
9. Laminar flow hood mouse handling (Scanlaf Safe 1200) 
10. Combi-vet Anesthesia machine with 4 Flowmeters (Rothacher Medical GmbH) 
11. O2 Concentrator MIC 02 10 lpm for Anesthesia system (Rothacher Medical GmbH, catalog 
number: CV 10-101 MIC 10 lpm) 
12. Anesthetic waste gas filter (Aldasorber 1400g) 
13. Veterinary Anesthesia Induction chamber/for rodents (Rothacher Medical GmbH, catalog 
number: PS-0346) 
14. In vivo Imaging System (In-Vivo Xtreme II, BRUKER) 
15. In-Vivo XtremeTM II SPF animal chamber (SPFC) with HEPA filters (BRUKER) 
16. Inverted microscope (Olympus CKX41) 
17. Inverted confocal microscope (Zeiss LSM 800) 
18. Computer (Windows 7) 
 
Software 
 
1. Molecular Imaging (MI) software version v. 7.5.3.22464 (BRUKER)  
2. GraphPad Prism software version 8.1.0 (GraphPad) 
 
Procedure 
 
A. Preparation of luciferase-expressing transfectants of Leishmania guyanensis (Lgy) parasites  
Note: The parasites are derived from the parental strain Lgy M4147 (MHOM/BR/75/M4147) and 
express firefly luciferase (5 x 107 photons/sec/106 parasites) from a LUC gene integrated stably into 
the small subunit of the ribosomal RNA locus (Lye et al., 2010). Stock parasites are maintained in 
liquid nitrogen. When starting from a frozen vial, thaw the parasites quickly by immersing the vial in 
a water bath at 26 °C. Transfer the parasites to a 15 ml tube and add 5 ml of Schneider medium 
(incomplete), resuspend and centrifuge at 2000 x g for 8 min at 26 °C. Remove the supernatant, 
resuspend in 5 ml of complete parasite culture medium and transfer into a 25 cm2 flask. Incubate at 
26 °C and 5% CO2. The parasites were passaged in culture for not more than five passages. The 
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parasites are isolated from mouse footpads to maintain their virulence and avoiding purification of 
metacyclic promastigotes and thus diminishing the risk of LPS contamination which could occur 
during purification and would activate the innate immune response and possibly affect read-outs. 
 
1. Dilute 100 μl of parasites (around 5 x 106 parasites) in 10 ml of complete parasite culture medium 
using 25 cm2 flask (Recipe 1).  
2. Incubate the parasites for 6 days at 26 °C and 5% CO2. 
3. At Day 6 of culture, verify that the parasites are in stationary growth phase (Figure 1). 
Note: Parasites are counted every day, once they reach their stationary phase, they are used 
for mice infection. 
4. Count the parasites: 
a. Remove 10 μl of the parasite culture and transfer it to a 1.5 ml microcentrifuge tube 
containing 990 μl of parasite fixative solution (Recipe 5). 
b. Wait for 3 min. 
c. Take 10 μl and place in the counting chamber. 
d. Count the parasites using an inverted microscope with 20x objective. 
5. Adjust parasite number to 20 x 106/ml in DPBS.  
 
Figure 1. Lgy parasites after 6 days in culture. Representative images of parasites in 
stationary phase forming large clumps, also known as “rosettes”. A. 10x objective without zoom. 
B. 10x objective with 4x zoom. Bright-field images using confocal microscope. The scale bar 
represents 20 μm.  
B. Mice infection with Lgy parasites 
Notes: 
a. All mice handling steps are performed in clean conditions under a laminar flow hood. We use 
C57BL/6 because they show a healing phenotype and therefore less gravity on the mice and 
even with a darker tissue, light transmission can be measured (Ives et al., 2011).  
b. Parasites are directly inoculated into the mice after adjusting to 20 x 106 parasites/ml. Injection 
of parasites can be performed in one or both footpads without any difference. 
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1. Slightly anesthetize the mice: 
a. Fill the isoflurane tank (Video 1, part 1).  
b. Switch on the O2 concentrator. 
c. Set the adjusting knob of the Combi-vet Anesthesia machine at 3% of isoflurane 
concentration. 
d. Switch on the flowmeter connected to the induction chamber. 
e. Transfer the mice to the induction chamber and slightly anesthetize them. 
2. Inject subcutaneously 50 μl of parasites at 20 x 106/ml in one, or both, hind footpads per mouse 
using U-100 insulin syringe (final Lgy concentration: 106 parasites per footpad).  
 
 
Video 1. Luciferin injection and image acquisition demonstration. The video demonstrates 
how to use the isoflurane anesthesia system, injection of luciferin in mice (Step C2), mice 
anesthesia and transfer to SPFC chamber (Step C3) and image acquisition using the In-vivo 
Xtreme II system (Step C4). 
 
C. Parasite burden quantification by Bioluminescence using In-Vivo Xtreme II 
Parasite burden can be determined either immediately after parasite infection or along the time-
course of the experiment. 5 mice at a time can be imaged.  
1. Start the In-Vivo Xtreme II system and set up the Bioluminescent protocol. 
a. Switch on the apparatus. 
b. Wait for 2 min before starting the computer. 
c. Once the computer is on, access the MI software and select Capture Xtreme BI 4MP. 
d. Allow the camera to reach its working temperature of -90 °C. The CCD Operating 
Temperature box will change from red to green when the camera is ready to use. 
Note: The duration of this step is approximate 10 min. 
e. Input predetermined capture parameters (Table 1) (see Note): 
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Table 1. Capture values for the different modalities. Modality: imaging modes available in the In-
Vivo Xtreme II (fluorescence, luminescence, X-Ray and reflectance). Exposure time: duration of 
time the camera collects light (seconds, minutes). Mode: way the camera captures the image. kVp: 
maximum tension applied across an X-Ray tube. Binning: process of combination of neighboring 
pixels on an image sensor into one “super pixel”. fSTOP: aperture of the diaphragm of the camera. 
FOV: Field of view. Focal plane: focus.  
Modality Exposure 
time 
Mode Filters Binning 
(Pixels) 
fSTOP FOV 
(cm) 
Focal plane 
(mm) 
Luminescence 5 min High 
Sensitivity 
- 4 x 4 1.1 19  0 
X-Ray  5 s High Speed XRay: 0.4 mm 
kVp: 45 
1 x 1  4 19 0 
Reflectance 1 s High Speed - 1 x 1 4 19 0 
 
f. Save the parameters in Step C1e as individual session files. 
g. Create a protocol by selecting the Create/Edit Protocols button from the system interface 
acquire window. 
h. Select the previously luminescence session file as Step C1. Next, select the corresponding 
X-Ray session file as Step C2. Finally, choose the reflectance session file as in Step C3. 
Keep–Do nothing–in both Before and After Image Capturer in the 3 Steps of the protocol. 
i. Save the protocol. 
2. Injection of luciferin solution in mice (Video 1, part 2) 
a. Inject intraperitoneally 200 μl of luciferin solution (Recipe 6) at a final dose of 150 mg/kg/ 
mouse using U-100 insulin syringe (see Note). 
b. Wait for 10 min after luciferin administration before starting image acquisition. 
Note: Mice are not anesthetized during luciferin injection. Light of the laminar hood is turned 
off during injection of luciferin in mice. 
3. Isoflurane anesthesia and transfer to the SPFC chamber (Video 1, parts 3, 4, 5 and 6) 6-7 min 
after injection of luciferin in mice. 
a. Repeat Procedure B for mice anesthesia using the induction chamber.  
b. Transfer the anesthetized mice to the individual nosecones of the SPFC chamber connected 
to the isoflurane system (Figure 2A). 
4. Introduction of SPFC chamber into the In-Vivo Xtreme system and image acquisition (Video 1, 
parts 6, 7 and 8) 10 min after injection of luciferin in mice. 
a. Switch on the isoflurane system connected to the imaging system. 
b. Insert the SPFC chamber to the In-Vivo Xtreme machine. 
c. Connect all the isoflurane pipes to the SPFC (Figure 2B). 
d. Execute the previously saved protocol (Step C1i) by clicking Execute Protocol button from 
the main acquire window interface. During the execution of the protocol, notice a status 
window providing real time report of the current capture, the exposure duration as well as 
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the protocol step. 
e. After image capture, remove the SPFC chamber from the imaging system and switch off 
the isoflurane system. 
f. Transfer the anesthetized mice to their cage and monitor the animals until they are fully 
recovered.  
g. Open the acquired images in the MI software for visual inspection and region of interest 
(ROI) analysis. 
 
 
Figure 2. SPFC chamber. A. SPFC chamber connected to the isoflurane system for introducing 
the anesthetized mice. B. SPFC chamber at the Xtreme II system connected to the isoflurane 
system.  
Data analysis 
 
A. Image Overlay 
Luminescence image overlay can be performed either with X-Ray or Reflectance image. 
Example using Luminescence and X-Ray images: 
1. Open the Luminescence (foreground) image with the MI software (Figure 3A). 
2. Remove the background of the Luminescence image by clicking on Image Display tab on the 
top bar and set the Min/Max values (Figure 3B). 
Note: Min/Max range differs from study to study depending on the luminescence intensity 
captured. Images should be contrasted with a Min/Max that shows specific signal avoiding any 
unspecific background signal. 
3. Convert to Photons/s/mm2 (Figure 3C). 
4. Open the X-Ray (background) image with the MI software (Figure 3D). 
5. Click the Overlay option from the Image Display tab, select the Luminescence image and 
choose the Transparency option (Figure 3E). 
6. To extract the overlayed image, select the Annotations option from the Navigation menu (Figure 
3F). Add any additional data or object to the overlay. Once all the annotations are included, 
select the Select all option from the Edit top tab. Copy and paste the overlayed image into the 
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desired file (e.g., Word, PowerPoint, Photoshop) for display. 
 
B. Image Analysis  
Luminescence intensity quantification. 5 mice can be analyzed at a time.  
1. Repeat steps1-4 from the Image Overlay section. 
2. Open the Manual ROIs tab from the Navigation panel and click on New ROI set (Figure 3F). 
3. Create an ROI set and adjust it to better enclose the luminescence intensity detected (Figure 
3G). 
Note: The ROI set can be saved as Template for the following image analysis using the same 
experiment layout. 
4. To view the quantitative results, select the Analysis tab from the top Menu bar and select the 
Display tab (Figure 3H). 
5. From the Display option, select the desired parameters and then click OK. 
6. Copy the results obtained and paste them into the appropriate file for further analysis (e.g., Word, 
Excel, GraphPad Prism). e.g., Copy the Sum values from the Analysis tab (Figure 3H) to 
GraphPad Prism software. Represent the data as mean and ±SD or SEM (Figure 3I). 
7. Save the image so the ROI analysis is available. 
The measure of parasite luminescence during the whole course of Lgy infection (Figure 3J) allows 
the study of disease progression. In the case of Lgy infection, the peak of footpad swelling is at 4 
weeks post-infection and resolves by 8 weeks post-infection (Ives et al., 2011; Hartley et al., 2016). 
These results are observed in Figure 3J, parasite burden peaks at 4 weeks post-infection and it 
drastically diminishes by 8 weeks post-infection.   
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Figure 3. Monitoring the level of bioluminescence activity in the footpad after 
subcutaneous inoculation of 106 luciferase-transfected Lgy: an example of Image 
Overlay and Image Analysis. A-C. Step by step analysis of removing the background from a 
luminescence capture and converting the intensity to photons/sec/mm2. D. Example of X-Ray 
capture. E. Overlay of C + D images. F. Navigation display. G. Overlay with the set of ROIs. H. 
Quantitative results obtained from the Analysis tab. I. Parasite burden from Lgy infected mice 
footpads at 4 weeks post-infection (H Sum column, photons/sec) using GraphPad Prism 
software. J. Parasite burden kinetics from Lgy infected mice footpads (Sum, photons/sec). I-J. 
Data represent mean and ±SEM from 5 mice.     
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Notes 
 
1. Capture parameters were predetermined with the help of Bruker Corporation (BRUKER).  
Luminescence modality: Luminescence signal is low in our experimental model. We use an 
exposure time of 5 min to increase the signal detection, but also taking into account to minimize 
the mice anesthesia. High sensitivity mode in order to reduce the background and increase the 
sensitivity of the luminescent signal. Binning of 4x4 increases the intensity of the signal but does 
not matter if it lowers the resolution of the image. Large aperture (fSTOP 1.1) helps to improve 
the detection of weak signal such as luminescence. FOV 19 allows imaging 5 mice/capture.  
XRay and Reflectance modalities: Exposure time is in seconds and high-speed mode since the 
signal is strong. Binning 1x1 (no binning) and fSTOP 4 increase the resolution and the depth of 
field in the image, respectively. 45 kVp is used for X-Ray capture as it allows better bone 
resolution in vivo.  
 
Recipes 
 
1. Complete parasite culture medium 
500 ml Schneider’s Drosophila Medium 
100 ml heat-inactivated FBS (Recipe 2) 
5 ml HEPES 
5 ml P/S 
250 μl Biopterin (Recipe 3) 
1 ml Hemin-folate (Recipe 4) 
Filter all the reagents using Vacuum Filtration 500-Filtermax, aliquot and store at 4 °C 
2. Heat-inactivated FBS 
Thaw the FBS at RT. Then, perform heat-inactivation by incubating the FBS in a water bath at 
56 °C for 30 min. Aliquot and store at -20 °C 
3. Biopterin 
Biopterin is reconstituted to a concentration of 1.2 mg/ml in DMSO. Aliquot and store at -20 °C  
4. Hemin-folate 
Dissolve 100 g hemin and 200 g folic acid in 20 ml 0.1 M NaOH 
Add 40 ml of H2O 
Adjust the pH to 8  
Autoclave 
Aliquot and store at 4 °C 
5. Parasite fixative solution  
48 ml DPBS 
2 ml Glutaraldehyde solution technical 
Store at 4 °C 
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6. Luciferin solution 
66.6 ml DPBS 
1 g VivoGloTM Luciferin 
Luciferin is reconstituted to a concentration of 15 mg/ml in DPBS. Filter the solution using a 0.22 
μm pore size filter and 50 ml syringe. Aliquot and store at -20 °C. Aliquots are thawed at RT 
prior to injection  
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